Discovery of a structurally novel opioid κ-agonist derived from 4,5- epoxymorphinan

DOI: 10.1248/cpb.46.366

Source and publish data:

Chemical and Pharmaceutical Bulletin p. 366 - 369 (1998)

Update date:2022-08-11

Topics:

Authors:

Nagase, Hiroshi

Hayakawa, Jun

Kawamura, Kuniaki

Kawai, Kouji

Takezawa, Yuko

Matsuura, Hirotoshi

Tajima, Chiko

Endo, Takashi

Read Full Text PDF DownLoad Join now for total 90,000,000 free articles

Article abstract of DOI:10.1248/cpb.46.366

A new type of κ-agonist, 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α- epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride (1, TRK-820), was discovered by a new working hypothesis. The 'message-address concept' for opioid antagonists and the 'accessory site' for general antagonists were applied to design TRK-820. A unique structural feature of TRK-820, which is different from other prototypical κ-opioid receptor agonists, is the existence of the 4,5-epoxymorphinan structure with a tyrosine-glysine moiety for endogenous opioid peptides such as dynorphins. TRK-820 exhibited high potency and high κ-selectivity in guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations. In the mouse acetic-acid- induced writhing model and mouse tail flick model of antinociception, TRK- 820 was 85-140 times more potent than morphine and 85-350 times more potent than U-50488H. This structurally novel κ-agonist showed neither aversion nor preference in the Conditioned Place Preference test, in spite of the fact that prototypes of κ-agonists (U-50488H derivatives) demonstrated aversion.